XKRX
053030
Market cap150mUSD
Oct 08, Last price
6,340.00KRW
1D
-2.61%
1Q
-11.33%
Jan 2017
-62.60%
IPO
4.97%
Name
Binex Co Ltd
Chart & performance
P/E
—
P/S
1.20
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.48%
Rev. gr., 5y
4.85%
Revenues
168.47b
+29.55%
Net income
-3.23b
L-90.80%
CFO
-23.61b
L+150.53%
Dividend
Dec 29, 2008200 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BINEX Co., Ltd. operates as a pharmaceutical enterprise based in South Korea. The company provides an extensive array of medicinal products, encompassing bisroot items, gastrointestinal treatments (including antispasmodics and antiulcerants), NSAIDs, cardiovascular and urology medications, hepatic protective agents, topical ointments and creams, ophthalmic solutions, CNS agents, digestive aids, remedies for constipation and circulation, antibiotics and antifungals, cough and cold preparations, vitamins and nutritional supplements, antihistamines, antivertigo agents, and over-the-counter (OTC) drugs. Additionally, BINEX Co., Ltd. maintains a co-development alliance with Genexine, Inc. focused on the creation of a COVID-19 vaccine. Founded in 1957, its headquarters are situated in Incheon, South Korea.
Key people
President, Chief Executive Officer, Director · since 2015
Vice President · since 2022
Hyeong Yil Lee
Vice President
Jin Seop Cho
Assistant Managing Director
Jin Sun Choi
Internal Auditor
Jae Pil Gong
Assistant Managing Director
Su Yong Jin
Assistant Managing Director · since 2015
Ji Yeong Kim
Assistant Managing Director
Jin Su Lee
Assistant Managing Director
Bong Su Seo
Assistant Managing Director
Eun Seok Son
Assistant Managing Director
Gyeong Yil Yang
Assistant Managing Director
Myeong Ho Jung
Chairman · since 2015
Myeong Cheol Lee
Vice President, Director · since 2020
Non-Executive Independent Director · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||